PRNewswire (Thu, 22-Jan 10:00 AM ET)
Pomerantz Investigates XOMA Following Failed Phase 3 Trial and Sharp Stock Reaction
Market Chameleon (Fri, 16-Jan 5:33 AM ET)
XOMA Royalty Announces CFO Transition
Globe Newswire (Mon, 12-Jan 7:30 AM ET)
Investigation Launch Prompts Renewed Scrutiny for XOMA Royalty Corporation Amid Clinical Setback
Market Chameleon (Thu, 8-Jan 6:55 AM ET)
Globe Newswire (Tue, 30-Dec 7:30 AM ET)
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Globe Newswire (Mon, 22-Dec 7:30 AM ET)
XOMA Royalty’s Acquisition of Generation Bio Unlocks New Royalty Streams and Platform Value
Market Chameleon (Tue, 16-Dec 3:33 AM ET)
XOMA Royalty Enters into Agreement to Acquire Generation Bio
Globe Newswire (Mon, 15-Dec 5:00 PM ET)
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Globe Newswire (Fri, 5-Dec 7:45 AM ET)
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Xoma Royalty trades on the NASDAQ stock market under the symbol XOMA.
As of January 26, 2026, XOMA stock price declined to $25.86 with 761,476 million shares trading.
XOMA has a beta of 1.33, meaning it tends to be more sensitive to market movements. XOMA has a correlation of 0.22 to the broad based SPY ETF.
XOMA has a market cap of $320.23 million. This is considered a Small Cap stock.
Last quarter Xoma Royalty reported $9 million in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.28.
In the last 3 years, XOMA traded as high as $39.92 and as low as $13.48.
The top ETF exchange traded funds that XOMA belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
XOMA has underperformed the market in the last year with a price return of -0.6% while the SPY ETF gained +14.8%. XOMA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.5% and -13.4%, respectively, while the SPY returned +3.4% and -0.2%, respectively.
XOMA support price is $25.37 and resistance is $28.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XOMA shares will trade within this expected range on the day.
